Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.48 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.39 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28385111 | 0.99 | MAP2K1 (0.48) | MAP2K1MAP2K2FLT1IDO1MAP2K5 | |
| SCHEMBL30486884 | 0.91 | MAP2K1 (0.44) | MAP2K1MAP2K2FLT1MAP2K5EIF2AK1 | |
| SCHEMBL21979490 | 0.91 | MAP2K1 (0.44) | MAP2K1MAP2K2FLT1MAP2K5EIF2AK1 | |
| SCHEMBL22039975 | 0.88 | MAP2K1 (0.42) | MAP2K1MAP2K2FLT1MAP2K5EIF2AK1 | |
| SCHEMBL30486891 | 0.88 | MAP2K1 (0.42) | MAP2K1MAP2K2FLT1MAP2K5EIF2AK1 | |
| SCHEMBL29376483 | 0.88 | MAP2K1 (0.42) | MAP2K1MAP2K2FLT1MAP2K5EIF2AK1 | |
| SCHEMBL21979498 | 0.85 | MAP2K1 (0.61) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL30486893 | 0.85 | MAP2K1 (0.61) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL21979482 | 0.82 | MAP2K1 (0.52) | MAP2K1MAP2K2IDO1 | |
| Hydrochloric Acid SCHEMBL28385113 | 0.81 | MAP2K1 (0.51) | MAP2K1MAP2K2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200165243-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885MAP2K2 3533/4885FLT1 2710/4885 |
| US-20200165243-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | MAP2K1 434/4885MAP2K2 265/4885FLT1 1307/4885 |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | MAP2K1 435/4885MAP2K2 263/4885FLT1 1278/4885 |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | MAP2K1 470/4885MAP2K2 286/4885FLT1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.